Navigation Links
UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
Date:2/10/2011

HOUSTON and LOS ANGELES February 10th, 2011 Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke. The study, conducted by leading researchers from the Department of Neurology at the UTHealth Medical School working in collaboration with scientists at Athersys, illustrated the potential benefits of MultiStem therapy for treating stroke. Researchers observed that intravenous administration of MultiStem one day after a stroke reduced inflammatory damage in the brain and resulted in a significant improvement in motor skills.

"We are seeing a paradigm shift in the way some types of stem cells may enhance recovery from stroke," said Sean I. Savitz, M.D., principal investigator and associate professor of neurology at UTHealth. "The stem cells may actually exert some of their effects on other organs such as the spleen. The spleen seems to play an important role in some neurological disorders by contributing, for example, to ongoing inflammation and brain injury after stroke. We're finding these stem cells are working on dampening inflammation involving the spleen."

According to the American Heart Association, approximately 800,000 individuals suffer a stroke each year in the United States, and an estimated 2 million individuals suffer a stroke each year in the U.S., Japan, and major European countries combined. Approximately 85% of strokes are ischemic, meaning they are caused by a blockage of blood flow in the brain, which occurs as a result of a clot or "thrombus". Currently there is only one FDA-approved drug therapy for the treatment of ischemic stroke, the thrombolytic tPA, which helps to dissolve the flow-impeding blood clot. H
'/>"/>

Contact: Deborah Mann Lake
deborah.m.lake@uth.tmc.edu
University of Texas Health Science Center at Houston
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UTHealth, BioHouston sign collaborative agreement
2. Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010
3. Cell-enriched fat grafts improve long term graft retention in preclinical study
4. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
5. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
6. Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
7. Versartis presents positive preclinical data on 2 product candidates at ENDO 09
8. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
9. Preclinical work shows how one gene causes severe mental retardation
10. Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
11. New evolutionary research disproves living missing link theories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... -- For more than four decades, AUVSI,s Unmanned Systems ... worldwide event for the unmanned land, sea, and air ... any local, national, or trade news organization interested in ... current applications of unmanned technologies. The conference will explore ... industry, and how it will soon impact the lives ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Tampa, Fla. (Mar. 12, 2009) A study to ... from a combination of autologous (patient self-donated) stem cell ... of ) oxygen treatment (HBO) before and after ASC ... glycemic control" along with "reduced insulin requirements." The combination ...
... a profound role in regulating global climate. But the ... have long struggled to accurately measure their composition, size, ... new satellite instrument developed by NASA scientists, the Aerosol ... Some types of small aerosols -- such as black ...
... software developed with help from the Wildlife Conservation Society ... by creating a three-dimensional model using photos taken by ... of the journal Biology Letters , may also ... The new software, developed by Conservation Research Ltd., creates ...
Cached Biology News:Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes 2New aerosol observing technique turns gray skies to blue 2New aerosol observing technique turns gray skies to blue 3New aerosol observing technique turns gray skies to blue 4Tracking tigers in 3-D 2
(Date:5/27/2015)... Madison, NJ (PRWEB) May 27, 2015 ... for evaluating the impact of regulation on medical innovation, ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ... inaugural MI3 Alert pertains to new FDA ... Senate proposal for accelerating the approval of certain medical ...
(Date:5/26/2015)... WORMS, GERMANY – May 26, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent organization that certifies manufacturers, suppliers, ... All three Grace facilities that produce its SYLOID® ... have now received GMP certification, following the Curtis ...
(Date:5/26/2015)... , May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... president and CEO, will provide an update on the progress ... overview of the company,s business strategy at 1:30pm ET on ... Conference. The conference is being held in New ... webcast live and may be accessed via a link on ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Global ... have announced plans for the company’s first cellular and ... followed by a full day, hands-on stem cell training ... J. Victor Garcia Gimenez, M.D., President of Therapeutic Confrontations ... medical community’s increasing interest in regenerative medicine and recent ...
Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
... continue to have access to ZEVALIN(R) and other novel ... ... New Medicare legislation,passed by the House and Senate extends the ... and Medicaid,Services (CMS) had implemented new hospital outpatient reimbursement rates,for ...
... (Nasdaq: ALXA ) announced today that it has ... Directors. Dr. Barron is currently,Senior Vice President, Development and ... organization, which is responsible for,pre-clinical, clinical and post-approval activities., ... clinical scientist and was,promoted in 2002 to Vice President ...
... Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... chaperones for the treatment of human,genetic diseases, ... Phase 2 clinical trials of Amigal(TM) (migalastat ... Amigal is being developed in,partnership with Shire ...
Cached Biology Technology:House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 2House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 3Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 2Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 4Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 5Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 6
... is an optical unit that can be ... Dyad Disciple gradient-capable thermal cycler (purchased separately). ... shuttle that contains four LEDs for fluorescence ... 620-650 nm) and two filtered photodiodes for ...
... (LCM) is the method of choice for ... the only instrument to offer both LCM ... UV Laser Cutting provides unprecedented ... and capturing large numbers of cells. , ...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: